Randomized, Phase 2, Dose-Ranging Study in the Treatment of Rosacea With Encapsulated Benzoyl Peroxide Gel

June 2014 | Volume 13 | Issue 6 | Original Article | 685 | Copyright © June 2014


James J. Leyden MD

University of Pennsylvania, Philadelphia, PA

table 3
acnes has not been associated with PPR but in view of the effectiveness of benzoyl peroxide this deserves study.
Patients tolerated the E-BPO formulations extremely well, which is striking in view of the increased sensitivity of facial skin of rosacea patients. Encapsulation of benzoyl peroxide clearly protected the epidermis from the potential irritant effects.
In summary, we found 1% and 5% benzoyl peroxide encapsulated in silica microcapsules, to be highly effective and well tolerated in PPR. These results need to be replicated in larger clinical trials to further confirm the safety and efficacy findings.

DISCLOSURES

The author has not disclosed any relevant conflicts.

REFERENCES

  1. Powell FC. The histopathology of rosacea: ‘where’s the beef?’. Dermatology.2004;209:173-174.
  2. Powell FC. Rosacea and the pilosebaceous follicle. Cutis. 2004;74:9-12, 32-4. Review.
  3. Steinhoff M, Buddenkotle J, Aubert J et al. Clinical, cellular and molecular aspects in the pathophysiology of rosacea. J Inves. Derm 2011;15:2-11.
  4. Yamasaki K, Gallo R. Rosacea as a disease of cathelicidious and skin innate immunity. J Invest Derm. 2011;15:12-15.
  5. Schwab VD, Sulk M, Seeliger S et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Invest Dermatol Symp Proc. 2011;15:53-62.
  6. Forton FMN. Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol. 2012;26:19-28.
  7. Elewski BE, Fleischer AB Jr, Pariser DM et al. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-50.
  8. Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large community- based study of metronidazole gel in rosacea. Cutis. 2007;79:73-80.
  9. Del Rosso JQ, Webster GF, Jackson M et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791-802.
  10. Breneman D, Savin R, VandePol C et al. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43:381-7.
  11. Gold M, Farber H, Gilboa R, Tschen E. Use of benzoyl peroxide/clindamycin gel in the once daily treatment of moderate rosacea. Poster presented at 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, LA P161.
  12. Toledano O, Abu-Reziq R, Bar-Simantov H, Bilman N, Sertchook H, Shapiro L, Sommer WT, Sriadibhatla S. Method for Preparing Particles Comprising Metal Oxide Coating and Particles with Metal Oxide Coating. Published Patent Application WO 2008/093347 (2008).
  13. Toledano O, Mavor D, Drori E, Hershkovitch S, Erlich M. Topical Compositions Containing Coated Active Agents. Published Patent Application WO 2010/076803 (2010).
  14. O’Reilly N, Bergin D, Reeves EP, McElvaney NG, Kavanagh K. Demodex-Associated Bacterial Proteins Induce Neutrophil Activation. Brit J Dermatol. 2012;166, 753-760.

AUTHOR CORRESPONDENCE

James J. Leyden MDjjleyden@mindspring.com
Close Menu